CUE · Cue Biopharma, Inc.
$24.80
-1.07 (-4.14%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 14, 2026
The latest filing no longer states the doubt (first flagged May 14, 2026).
View the 10-Q filed Aug 14, 2026Market Cap
$194.11M
Shares
7.26M
Volume · Oct 1
183.45K
Avg daily vol (3M)
260.76K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$25.87
Open$25.89
Day$24.88–27.43
52W close$5.31–37.84
Avg vol 30d348K
Short int332K · 4.6% float · 2.4d
Short vol70%
Last earningsSep 21, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 14
Up next
Next earnings call
May 7, 2027
Est · unconfirmed
· in 31 wks
filed Aug 14, 2026
call held Jun 30, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$37.65M
Trailing 12 months
Net income (TTM)
−$164.11M
Trailing 12 months
Revenue growth YoY
+166.7%
Year over year
Operating margin
-262.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-25.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+99.3%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
4.6%
Latest settlement · 2.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+29%
above
Price vs 50-day avg
−11%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
63%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
+194%
trailing
YTD return
+183%
this year
Relative strength
+182%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $29 › 200d $20 — 50d above 200d
Institutional flow
Distributing
-12% holders QoQ · +14 funds added
Insider flow
Distributing
Net -$2.0M over 90 days · 100% sells
Short interest
Rising
4.57% of float · ▲ +4.3% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
51 holders — mid 3-yr range
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
+196%
Y/Y
EPS growth
+61%
Y/Y
Free cash flow
$-21.9M
Balance sheet
$22.4M
net cash
Quant / Vol
risk profile
Volatility
199%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
16.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+29%
Bullish
Price vs 50-day avg
−11%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
63%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $29 › 200d $20 — 50d above 200d
Institutional flow
Distributing
-12% holders QoQ · +14 funds added
Insider flow
Distributing
Net -$2.0M over 90 days · 100% sells
Short interest
Rising
4.57% of float · ▲ +4.3% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
51 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $26 · 63%
Range high $38
vs 200-day avg +29%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CUE
this stock
Cue Biopharma, Inc.
|
$194.11M | — | +195.7% | — | 4.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CUE | -18.4% | -9.0% | +194.3% | +1.4% | +182.7% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -17.8% | -9.2% | +182.1% | +2.0% | +170.9% |